US 7,569,577 B2
	Quinazoline derivatives as tyrosine kinase inhibitors
Laurent Francois Andre Hennequin, Reims (France); and Christopher Thomas Halsall, Macclesfield (United Kingdom)
Assigned to Astrazeneca AB, Sodertalje (Sweden)
Appl. No. 10/573,090 PCT Filed Sep. 13, 2004, PCT No. PCT/GB2004/003923 § 371(c)(1), (2), (4) Date Mar. 15, 2006, PCT Pub. No. WO2005/026150, PCT Pub. Date Mar. 24, 2005.
Claims priority of application No. 0321620.7 (GB), filed on Sep. 16, 2003; and application No. 0406163.6 (GB), filed on Mar. 19, 2004.
Prior Publication US 2007/0043009 A1, Feb. 22, 2007
Int. Cl. A61K 31/517 (2006.01); C07D 239/94 (2006.01)

U.S. Cl. 514—266.22  [544/293]

18 Claims

1. A compound which is (2S)-1-[4-({4-[3-chloro-2-fluoroanilino]-6-methoxyquinazolin-7-yl}oxy)piperidin-1-yl]-1-oxopropan-2-ol, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable ester thereof.